Under construction – not a live service
Sign in
Taking peoplePhase 1/2

Tests BMS-986507 combinations in adults with advanced lung or breast cancer

Tests BMS-986507 with other drugs in adults with advanced cancer.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Tainan and Taipei, TaiwanSee the 2 sitesAlso in 9 other countries, 63 sites
Trial code
Registry title
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
416 people, planned
Started
4 Feb 2025
Expected to end
26 Feb 2031
Type of study
Interventional, 5 groups
Treatments tested
  • BMS-986507
  • Osimertinib
  • Pembrolizumab
  • Nivolumab
  • Pumitamig
Record updated
23 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced lung cancer (NSCLC) or advanced breast cancer (triple-negative or ER-low, HER2-negative) to test BMS-986507 combinations.

Age
18 years or older
Sex
All sexes can join
Disease stage
Locally advanced or metastatic non-small cell lung cancer (NSCLC), or locally advanced, recurrent inoperable or metastatic triple-negative breast cancer (TNBC) or ER-low, HER2-negative breast cancer. The cancer must be confirmed by pathology.
Earlier treatment
Not stated in the record.
Biomarker or test result
One lung cancer group needs an EGFR exon 19 deletion or L858R mutation in exon 21, or another EGFR mutation. The other lung cancer groups exclude people with known EGFR mutations.

Main reasons for not taking part

  • Mixed small cell and non-small cell lung cancer
  • Known EGFR mutations (lung cancer groups B and E, and group A as written in the record)
  • History of serious recurrent infections
  • History of severe heart disease
  • Other exclusion rules defined in the study protocol

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Participants must have at least one measurable lesion per response evaluation criteria in solid tumors
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Participants must have a life expectancy of at least 3 months at the time of the first dose
  • Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed
  • Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC
  • Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC
  • Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO/CAP criteria, based on the most recently analyzed biopsy or another pathology specimen
  • Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent

Who cannot take part

  • Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology
  • Participants must not have a history of serious recurrent infections
  • Participants must not have a history of severe heart disease
  • Participants with known mutations in EGFR will be excluded (Group A,B and E)
  • Other protocol-defined Inclusion/Exclusion criteria apply

Where in Taiwan

Also in 9 other countries, 63 sites

  • TainanHospital not named in the registryContact: Site 0147Not yet recruiting
  • TaipeiHospital not named in the registryContact: Site 0145Not yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

The 5 groups in the trial

  • Group ATreatment being tested

    Treatment: BMS-986507 and Osimertinib

  • Group BTreatment being tested

    Treatment: BMS-986507 and Pembrolizumab

  • Group CTreatment being tested

    Treatment: BMS-986507 and Nivolumab

  • Group DTreatment being tested

    Treatment: BMS-986507 and Pumitamig

  • Group ETreatment being tested

    Treatment: BMS-986507 and Pumitamig

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
Plain-language title
Tests BMS-986507 combinations in adults with advanced lung or breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 September 2026